This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Integra Announces Preliminary Q4 Results, Share Buyback Plan
by Zacks Equity Research
Integra (IART) projects fourth-quarter 2019 revenues at or near the low end of its previously-announced guidance.
Here's Why You Should Retain Integra LifeSciences Stock Now
by Zacks Equity Research
Investors can hold on to Integra LifeSciences (IART) stock in their portfolio owing to solid prospects.
IART vs. TCMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
IART vs. TCMD: Which Stock Is the Better Value Option?
Integra LifeSciences' (IART) Earnings Top Estimates in Q3
by Zacks Equity Research
We are upbeat about the year-over-year revenue growth in Integra LifeSciences' (IART) Codman Specialty Surgical segment.
Integra LifeSciences (IART) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 4.62% and 0.66%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Integra LifeSciences (IART) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra Buys Rebound Therapeutics to Boost Neurosurgery Line
by Zacks Equity Research
Integra (IART) believes, Rebound's MIS technological arm will widen its neurosurgical pipeline within Codman Specialty Surgical space.
IART or GMED: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
IART vs. GMED: Which Stock Is the Better Value Option?
Integra LifeSciences' Organic Growth Strong on New Products
by Zacks Equity Research
Gaining traction from product unveilings and an improved sales force performance, Integra LifeSciences (IART) expects rapid organic growth in the second half of 2019.
Why Is Integra (IART) Down 1% Since Last Earnings Report?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medtronic (MDT) Beats on Q1 Earnings, Ups FY20 EPS Guidance
by Zacks Equity Research
Medtronic (MDT) displays improved performances at CER, banking on growth across all major segmental businesses as well as geographies.
IART or GMED: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
IART vs. GMED: Which Stock Is the Better Value Option?
Moving Average Crossover Alert: Integra LifeSciences
by Zacks Equity Research
Integra LifeSciences Holdings Corporation (IART) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
IART vs. ABMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
IART vs. ABMD: Which Stock Is the Better Value Option?
Integra Lifesciences' (IART) Earnings Top Estimates in Q2
by Zacks Equity Research
We are upbeat about Integra LifeSciences' (IART) year-over-year revenue growth across key business segments.
Integra LifeSciences (IART) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 12.31% and 2.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Integra LifeSciences (IART) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra Partners AI-Driven Data Analytics Firm in Wound Care
by Zacks Equity Research
Integra LifeSciences (IART) expects its partnership with Tissue Analytics to be perfectly strategic as the latter's software solutions automatically derive high quality data from clinical pictures.
Veracyte (VCYT) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Veracyte (VCYT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
IART vs. ABMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
IART vs. ABMD: Which Stock Is the Better Value Option?
Integra LifeSciences' Organic Growth Strong on New Products
by Zacks Equity Research
Banking on product unveilings and a better sales force performance, Integra LifeSciences (IART) pins hopes on accelerated organic growth in the second half of 2019.
Integra (IART) Down 4.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold On to Integra LifeSciences Stock
by Zacks Equity Research
Investor confidence is still high on growth prospects of Integra LifeSciences (IART).
Integra LifeSciences Rides on Product Launch, Faces Rivalry
by Zacks Equity Research
Benefiting from new products and an improved sales force performance, Integra LifeSciences (IART) projects speedy organic growth in the second half of 2019.
Integra LifeSciences (IART) Q1 Earnings Beat, Margins Rise
by Zacks Equity Research
Integra LifeSciences' (IART) quarterly performance is majorly hurt by the company's exit from the transition services agreements covering Western Europe.